| 000 | 01911 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515002516.0 | ||
| 264 | 0 | _c20060123 | |
| 008 | 200601s 0 0 eng d | ||
| 022 | _a0953-816X | ||
| 024 | 7 |
_a10.1111/j.1460-9568.2005.04362.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVernon, A C | |
| 245 | 0 | 0 |
_aNeuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. _h[electronic resource] |
| 260 |
_bThe European journal of neuroscience _cOct 2005 |
||
| 300 |
_a1799-806 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBrain Chemistry _xdrug effects |
| 650 | 0 | 4 |
_aCell Death _xdrug effects |
| 650 | 0 | 4 |
_aChromatography, High Pressure Liquid _xmethods |
| 650 | 0 | 4 | _aDiagnostic Imaging |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aExcitatory Amino Acid Antagonists _xadministration & dosage |
| 650 | 0 | 4 |
_aFunctional Laterality _xphysiology |
| 650 | 0 | 4 |
_aImmunohistochemistry _xmethods |
| 650 | 0 | 4 | _aLigands |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aOxidopamine _xtoxicity |
| 650 | 0 | 4 |
_aParkinson Disease _xetiology |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aReceptors, Metabotropic Glutamate _xphysiology |
| 650 | 0 | 4 |
_aSubstantia Nigra _xdrug effects |
| 650 | 0 | 4 |
_aSympatholytics _xtoxicity |
| 650 | 0 | 4 |
_aTyrosine 3-Monooxygenase _xmetabolism |
| 700 | 1 | _aPalmer, S | |
| 700 | 1 | _aDatla, K P | |
| 700 | 1 | _aZbarsky, V | |
| 700 | 1 | _aCroucher, M J | |
| 700 | 1 | _aDexter, D T | |
| 773 | 0 |
_tThe European journal of neuroscience _gvol. 22 _gno. 7 _gp. 1799-806 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1460-9568.2005.04362.x _zAvailable from publisher's website |
| 999 |
_c15827907 _d15827907 |
||